This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis of COVID-19. We seek to understand whether there are early signatures that predict progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study participation is approximately 3 months.
Study Type
OBSERVATIONAL
Enrollment
494
The University of Arizona
Tucson, Arizona, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of Illinois at Chicago
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
Performance (discrimination / calibration) of models
Performance (discrimination / calibration) of models that predict the risk of development of ARDS and/or mortality among COVID-19 patients who present to the hospital for evaluation and treatment.
Time frame: From date of study enrollment until the date of first documented ARDS diagnosis or date of death from any cause, whichever comes first, assessed up to study end (estimated at 3 months).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Weill Cornell Medical College
New York, New York, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
Inova Health Care Services
Falls Church, Virginia, United States